文献速递炎症性肠病

糖皮质激素联合肿瘤坏死因子拮抗剂诱导克罗恩病缓解的系统综述与汇总Meta分析

Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: A Systematic Review and Pooled Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-06-20

该系统综述与汇总Meta分析检索MEDLINE、Embase和CENTRAL数据库至2016年1月20日,纳入14项抗TNF药物随机试验共4354例患者,比较诱导期继续口服糖皮质激素联合抗TNF治疗与单用抗TNF治疗的临床缓解和应答。结果显示联合激素组临床缓解率32.0%对单药组35.5%(OR 0.93;95%CI 0.74-1.17),临床应答率42.7%对46.8%(OR 0.84;95%CI 0.73-0.96),作者结论为联合激素并未提高临床改善率。

要点

  • 诱导期联合糖皮质激素与抗TNF治疗相比单用抗TNF,临床缓解率32.0%对35.5%(OR 0.93;95%CI 0.74-1.17)。
  • 联合激素组临床应答率42.7%低于单药组46.8%(OR 0.84;95%CI 0.73-0.96)。
  • 调整基线CDAI评分和合并免疫调节剂使用后上述结果不变。

核心结论

  • 基于抗TNF治疗活动性克罗恩病随机试验数据的Meta分析,诱导期接受糖皮质激素的患者相比未接受激素的患者并未有更高的临床改善率。
  • 鉴于上述发现和糖皮质激素使用的风险,临床医生应考虑对激素难治性克罗恩病患者在抗TNF诱导治疗期间早期减停激素。

研究设计与样本

  • 系统检索MEDLINE、Embase和CENTRAL数据库至2016年1月20日,纳入14项已批准用于克罗恩病治疗的抗TNF药物随机试验(阿达木单抗5项、赛妥珠单抗5项、英夫利西单抗4项)。
  • 对上述试验的个体患者数据和汇总数据进行汇总Meta分析,共纳入4354例接受抗TNF诱导治疗的患者,其中1653例(38.0%)接受糖皮质激素。

主要发现

  • 联合糖皮质激素与抗TNF药物诱导临床缓解率为32.0%,而抗TNF单药治疗为35.5%(OR 0.93;95%CI 0.74-1.17)。
  • 联合糖皮质激素与抗TNF药物诱导临床应答率为42.7%,而抗TNF单药治疗为46.8%(OR 0.84;95%CI 0.73-0.96)。
  • 调整基线CDAI评分和合并使用免疫调节剂后,上述结果未改变。

关键数值与推荐

  • 临床缓解定义为CDAI评分<150;临床应答定义为CDAI下降100分;评估时间点为诱导治疗结束时(治疗第4-14周)。

临床怎么用

  • 作者认为,鉴于上述发现和糖皮质激素使用的风险,临床医生应考虑对激素难治性克罗恩病患者在抗TNF诱导治疗期间早期减停激素。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: It is not clear whether concomitant therapy with corticosteroids and anti-tumor necrosis factor (TNF) agents is more effective at inducing remission in patients with Crohn's disease (CD) than anti-TNF monotherapy. We aimed to determine whether patients with active CD receiving corticosteroids during induction therapy with anti-TNF agents had higher rates of clinical improvement than patients not receiving corticosteroids during induction therapy. METHODS: We systematically searched the MEDLINE, Embase, and CENTRAL databases, through January 20, 2016, for randomized trials of anti-TNF agents approved for treatment of CD and identified 14 trials (5 of adalimumab, 5 of certolizumab, and 4 of infliximab). We conducted a pooled meta-analysis of individual patient and aggregated data from these trials. We compared data from participants who continued oral corticosteroids during induction with anti-TNF therapy to those treated with anti-TNF agents alone. The endpoints were clinical remission (CD activity index [CDAI] scores <150) and clinical response (a decrease in CDAI of 100 points) at the end of induction (weeks 4-14 of treatment). RESULTS: We included 4354 patients who received induction therapy with anti-TNF agents, including 1653 [38.0%] who were receiving corticosteroids. The combination of corticosteroids and an anti-TNF agent induced clinical remission in 32.0% of patients, whereas anti-TNF monotherapy induced clinical remission in 35.5% of patients (odds ratio [OR], 0.93; 95% CI, 0.74-1.17). The combination of corticosteroids and an anti-TNF agent induced a clinical response in 42.7% of patients, whereas anti-TNF monotherapy induced a clinical response in 46.8% (OR 0.84; 95% CI, 0.73-0.96). These findings did not change with adjustment for baseline CDAI scores and concurrent use of immunomodulators. CONCLUSIONS: Based on a meta-analysis of data from randomized trials of anti-TNF therapies in patients with active CD, patients receiving corticosteroids during induction therapy with anti-TNF agents did not have higher rates of clinical improvement compared with patients not receiving corticosteroids during induction therapy. Given these findings and the risks of corticosteroid use, clinicians should consider early weaning of corticosteroids during induction therapy with anti-TNF agents for patients with corticosteroid-refractory CD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Faleck DM, Shmidt E, Huang R, et al. Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: A Systematic Review and Pooled Meta-analysis. Clin Gastroenterol Hepatol. 2020. PMID: 32569749. doi:10.1016/j.cgh.2020.06.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。